BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...

BioMarin has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary ...

PR Newswire SAN RAFAEL, Calif., April 2, 2025 Company plans to submit for regulatory approval later this year SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceut ...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically ...

Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging ...

In 2019, Michael Rosenblum received an experimental new prostate cancer treatment after the disease spread to his bones. He remains symptom-free. The treatment is now approved for more patients. The ...

Whether you’re looking for no-rinse treatment or a creamy formula to combat brassiness, the best at-home gloss treatments are the excuse you’ve been seeking to reschedule your next salon visit ...

Sometimes blood clots lead to a heart attack or stroke. Treatments lower the number of red blood cells and prevent blood clots. They also relieve other symptoms, like headaches and vision problems.

"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut ...

evaluating the potential meaningful benefits of sepiapterin treatment in phenylketonuria or PKU patients. Sepiapterin has a dual mechanism of action to increase activity of the phenylalanine ...

ROCKVILLE, MD, UNITED STATES, March 20, 2025 /EINPresswire / -- According to a recently updated industry report released by Fact, the global phenylketonuria treatment market is expected to reach ...